Nurix Therapeutics, Inc.
NASDAQ: NRIX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Arthur T. Sands
- Employees
- 314
- Headquarters
- Brisbane, United States
- IPO year
- 2020
- Market cap
- $1.7B
- Website
- https://www.nurixtx.com
Loading NRIX…
Loading profile data…Frequently asked questions about NRIX
What does Nurix Therapeutics, Inc. (NRIX) do?
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials...
Where does NRIX trade?
Nurix Therapeutics, Inc. (NRIX) trades on the NASDAQ.
What sector is NRIX in?
Nurix Therapeutics, Inc. (NRIX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Nurix Therapeutics, Inc.?
Arthur T. Sands is the chief executive officer of Nurix Therapeutics, Inc. (NRIX).
Where is Nurix Therapeutics, Inc. headquartered?
Nurix Therapeutics, Inc. is headquartered in United States.
Does NRIX pay a dividend?
Nurix Therapeutics, Inc. (NRIX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NRIX go public?
Nurix Therapeutics, Inc. (NRIX) completed its initial public offering in 2020.